Last edition
News about
Alvotech Announces European Launch of Golimumab Biosimilar via Advanz Pharma
Alvotech has announced the European launch of AVT05, the first biosimilar to Simponi (golimumab), through its partner Advanz Pharma, following a tender award from NHS England in the UK to support market introduction.
WHO and AYUSH Ministry Hold Technical Meet on Integrating AYUSH into Global Health Standards
WHO and Ministry of AYUSH held a technical meeting to advance the integration of Ayurveda, Siddha and Unani (ASU) systems into global health standards, laying the groundwork for a Traditional Medicine (TM) module within the International Classification of Health Interventions (ICHI), with India supporting the required financial and technical frameworks.
Emcure Launches Poviztra to Broaden Access to Weight Management Therapy
Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.
US FDA Approves Roche's Lunsumio VELO for Subcutaneous Use in Follicular Lymphoma
The US FDA has approved Roche’s Lunsumio VELO for subcutaneous use in Relapsed or Refractory Follicular Lymphoma, cutting administration time to about one minute and supported by strong complete response data in later-line patients.
Samsung Biologics Expands US Manufacturing with HGS Acquisition from GSK
Samsung Biologics has acquired Human Genome Sciences (HGS) from GSK, securing its first US-based manufacturing site and strengthening its global supply network. The company plans further investments to expand capacity and capabilities at the facility, reinforcing its long-term commitment to the US biopharmaceutical manufacturing ecosystem.
Jacobio Pharma Signs Global Licensing Deal with AstraZeneca for Pan-KRAS Drug
Under the agreement, Jacobio will receive USD 100 million upfront and is eligible for up to USD 1.915 billion in development and commercial milestones, along with tiered royalties on ex-China sales, while AstraZeneca will lead all ex-China development, regulatory and commercial activities for JAB-23E73.
Sanofi and Novartis have separately entered into agreements with the US government to reduce medicine prices for American patients while reinforcing long-term commitments to US-based manufacturing, research and innovation, marking a coordinated push to balance affordability with sustained pharmaceutical investment.
Granules Pharma Gets US FDA Tentative Approval for Generic ADZENYS XR-ODT
Granules Pharmaceuticals Inc has received tentative approval from the US FDA for its generic version of Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT), which will be manufactured at the company’s US-based facility in Chantilly, Virginia.
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
AstraZeneca Secures CDSCO Approval for Breast Cancer Drug in India
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell and distribute its breast cancer therapy Datopotamab Deruxtecan in India.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy